Traumatic Brain Injury Market: Epidemiology, Therapies, Companies, DelveInsight | veriNOS pharmaceuticals GmbH, Cellvation, Abalonex, Hope Biosciences

The Traumatic Brain Injury (TBI) market is projected to grow in the coming years, driven by emerging therapies such as OXE103 (Ghrelin), HB-AdMSCs, ONP-002/PRV-002, CEVA101, MR-301, NE3107a, and others.

DelveInsight has released a detailed report titled "Traumatic Brain Injury - Market Insights, Epidemiology, and Market Forecast 2034", offering a comprehensive analysis of TBI, including historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key companies covered in the report include veriNOS Pharmaceuticals GmbH, Cellvation, Abalonex, and Hope Biosciences.

Discover about the Traumatic Brain Injury market report https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Traumatic Brain Injury Market Report:

The global traumatic brain injury (TBI) market is projected to experience steady growth from 2025 to 2034, largely fueled by the development of innovative therapies. According to DelveInsight, there were approximately 4.3 million new TBI cases across the 7MM (United States, EU5, and Japan) in 2024, with numbers expected to rise throughout the forecast period. The United States reported the highest incidence, followed by Japan, Germany, France, and the United Kingdom.
In terms of market value, the U.S. led in 2024, with standard care generating around USD 1.12 billion. Current treatment approaches primarily involve off-label use of medications, including antidepressants, antiepileptics, antipsychotics, analgesics, antacids, and other symptom-relief drugs. Notably, 45-85% of TBI patients rely on psychotropic and pain medications, underscoring the high dependence on pharmacologic management.
Promising therapies, such as AKUUGO for chronic TBI, have received multiple regulatory designations recognizing their potential. Emerging treatments like ONP-002, CEVA101, OXE103 (Ghrelin), HB-AdMSCs, MR-301, NE3107a, and others are expected to transform the TBI treatment landscape and drive market expansion. Companies including Oragenics, Beyond Barriers Therapeutics, Noveome, and Neuroplast are exploring innovative delivery methods, such as intranasal and intrathecal administration.
There is increasing recognition of the need to address both psychiatric and non-neurological symptoms in TBI patients, particularly among females, and to carefully assess medication regimens to mitigate risks associated with polypharmacy. As research advances and new therapies gain approval, the TBI market is poised for significant growth over the next decade.
In 2024, the United States recorded an estimated 3,042,000 TBI cases, the highest among the 7MM. Within the EU4 and the UK, Germany had the highest number of cases, followed by France, while Spain reported the lowest. In the UK specifically, approximately 125,000 adults and 49,000 children were affected.
Regulatory progress has also enhanced diagnostic capabilities. On April 2, 2024, the FDA approved Abbott's i-STAT TBI cartridge-a portable, whole-blood tool on the Alinity platform-providing lab-quality results in just 15 minutes to support concussion assessment and reduce unnecessary CT scans.
Key companies actively advancing TBI treatments include veriNOS Pharmaceuticals GmbH, Cellvation, Abalonex, and Hope Biosciences. Collectively, these emerging therapies and innovations are expected to reshape the TBI market landscape in the coming years.
Traumatic Brain Injury Overview

Traumatic brain injury (TBI) occurs when the brain sustains sudden damage due to a strong blow or jolt to the head. Common causes include motor vehicle accidents, falls, sports-related impacts, and physical assaults. The severity of TBI can range from mild concussions to serious injuries that result in long-term brain impairment. The immediate damage caused at the time of impact is known as the primary injury, which may affect a specific part of the brain or the brain as a whole. While skull fractures can occur, they are not always present. The brain may collide with the inner skull during trauma, causing bruising, bleeding, and damage to nerve fibers.

Symptoms of TBI vary according to injury severity and are typically categorized as mild, moderate, or severe. Mild TBI may involve brief loss of consciousness or no loss at all, with symptoms such as headache, dizziness, confusion, blurred vision, fatigue, ringing in the ears, sleep disturbances, mood or behavioral changes, and difficulties with memory or concentration.

Moderate to severe TBI symptoms are more pronounced and can include persistent or worsening headaches, repeated nausea or vomiting, seizures, inability to awaken, enlarged pupils, slurred speech, limb weakness or numbness, poor coordination, and heightened confusion or agitation.

Traumatic Brain Injury Market Outlook

Management of traumatic brain injury (TBI) typically involves a combination of medical care, rehabilitation, and supportive therapies designed to alleviate symptoms and promote recovery. Treatment strategies vary widely based on the injury's severity, ranging from standard cognitive therapy sessions to more complex procedures, such as bilateral decompressive craniotomies. While clinical guidelines provide a framework for TBI care, they must be tailored to the individual patient's specific needs and circumstances.

Current therapeutic approaches largely focus on symptom management and may involve the use of medications such as antidepressants, antiepileptics, antipsychotics, analgesics, antacids, and other supportive drugs. These treatments help address the neuropsychiatric, neurocognitive, and neurobehavioral effects commonly seen following brain injury.

Discover how the Traumatic Brain Injury market is rising in the coming years @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Traumatic Brain Injury Marketed Drugs

AKUUGO (Vandefitemcel): SanBio

Traumatic Brain Injury Emerging Drugs
OXE103: Oxeia Biopharmaceuticals
ONP-002: Oragenics

Scope of the Traumatic Brain Injury Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Traumatic Brain Injury Companies: veriNOS pharmaceuticals GmbH, Cellvation, Abalonex, Hope Biosciences, and others
Key Traumatic Brain Injury Therapies: OXE103 (Ghrelin), HB-AdMSCs, ONP-002 /PRV-002, CEVA101, MR-301, NE3107a, and others
Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Traumatic Brain Injury Unmet Needs, KOL's views, Analyst's views, Traumatic Brain Injury Market Access and Reimbursement

To know what's more in our Traumatic Brain Injury report, visit https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Traumatic Brain Injury Market Report:
Traumatic Brain Injury market report covers a descriptive overview and comprehensive insight of the Traumatic Brain Injury Epidemiology and Traumatic Brain Injury market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Traumatic Brain Injury market report provides insights into the current and emerging therapies.
The Traumatic Brain Injury market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Traumatic Brain Injury market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Traumatic Brain Injury market.

Got queries? Click here to know more about the Traumatic Brain Injury market Landscape https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Traumatic Brain Injury Patient Share (%) Overview at a Glance
5. Traumatic Brain Injury Market Overview at a Glance
6. Traumatic Brain Injury Disease Background and Overview
7. Traumatic Brain Injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Traumatic Brain Injury
9. Traumatic Brain Injury Current Treatment and Medical Practices
10. Unmet Needs
11. Traumatic Brain Injury Emerging Therapies
12. Traumatic Brain Injury Market Outlook
13. Country-Wise Traumatic Brain Injury Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Traumatic Brain Injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Traumatic Brain Injury Market Outlook 2034 https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Related Reports:

Traumatic Brain Injury Pipeline Insights, DelveInsight

"Traumatic Brain Injury Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Traumatic Brain Injury market. A detailed picture of the Traumatic Brain Injury pipeline landscape is provided, which includes the disease overview and Traumatic Brain Injury treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.